0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Protein > CD19 > CD9-H5259

Human CD19 (20-291) Protein, Fc Tag, low endotoxin

Order Now

  • Synonym
    CD19,B4,CVID3,MGC12802
  • Source
    Human CD19 (20-291), Fc Tag(CD9-H5259) is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).
    Predicted N-terminus: Pro 20
  • Molecular Characterization
    CD19 Structure

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 56.3 kDa. The protein migrates as 56-90 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.1 EU per μg by the LAL method.
  • Sterility
    Negative
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 6 months under sterile conditions after reconstitution.
SDS-PAGE
CD19 SDS-PAGE

Human CD19 (20-291), Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

Bioactivity-ELISA
 CD19 ELISA

Immobilized FMC63 at 1 μg/mL (100 μL/well) can bind Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5259) with a linear range of 0.039-0.625 μg/mL (QC tested).

 CD19 BATCH ELISA
 CD19 ELISA

Immobilized Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5259) at 5 μg/mL (100 μL/well) can bind FMC63 with a linear range of 0.6-20 ng/mL (QC tested).

 CD19 BATCH ELISA
Bioactivity-SPR
 CD19 SPR

Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5259) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Monoclonal Anti-Human CD19 Antibody (Mouse IgG2a) with an affinity constant of 0.467 nM as determined in a SPR assay (Biacore 8K) (QC tested).

  • Background
    B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €410.00

Price(EUR) : €2670.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:11 Details
  • Number of Drugs in Clinical Trials:291 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message